Licensing & Collaboration
Palatin is focusing resources on clinical trials with bremelanotide for female sexual dysfunction. Our research and technology has resulted in program opportunities outside our core clinical development strategy. Palatin is seeking partners to advance these opportunities, and will consider a variety of licensing or collaboration arrangements.
Several series of patented and patent-pending highly selective melanocortin receptor 1 agonists for use as anti-inflammatory agents and dermatological indications. Peptide series are highly specific (binding Ki at MCR1 as low as 0.01 nM) and selective (MCR1 to MCR4 Ki ratios of up to 10,000). Potential utility for inflammatory bowel disease and irritable bowel disease, inflammatory lung diseases such as asthma and COPD, ocular indications such as dry eye and dermatological indications.
Specific and selective melanocortin 4 receptor agonist peptides and small molecules for indications outside the sexual dysfunction market.
Natriuretic peptide compounds, include high-affinity NPR-C ligand, NPR-B agonists and dual NPR-A and NPR-B agonists.